UK Cancer Drugs Fund to be expanded for non-cancer therapies
The proposed ‘Innovative Medicines Fund’ extends the Cancer Drugs Fund (CDF) to include non-cancer diseases and is expected to be...
19
Mar
25
Feb
Japan’s First Pricing Reform Since 2013, expected in April 2021
Chuikyo, a key reimbursement policy panel of the Japanese Central Social Insurance Medical Council has approved the cost-effectiveness assessment (CEA)...
10
Feb
Cost-effectiveness and budget impact to be included in new IPTs
In Spain, The Ministry of Health announced that in 2021 the Therapeutic Positioning Reports (IPT) will be conducted under a...
20
Jan
Innovative CAR-T cell therapy set to be reimbursed by NICE
Tecartus (brexucabtagene autoleucel) is set to be reimbursed in England and Wales having received a recommendation for the Cancer Drugs...
14
Jan
New routes to marketing approval in Great Britain
As of 1st Jan 2021, Great Britain stopped following the EU centralised procedure for marketing authorisations. There are now many...
08
Jan
Best wishes from Prioritis
We hope this message finds you and your family in good health. The whole Prioritis team wishes you the very best...
12
Feb
EMA after Brexit? Prioritis continues to monitor the changes
The role of the EMA within the UK will continue until 31 December 2020. But the relationship remains uncertain from...
22
Oct
Prioritis at ISPOR Copenhagen stand C2-037
Prioritis has launched its PrismHEOR platforms reinforcing its unique offer of daily, intelligent and reliable published and upcoming data regarding...
18
Feb
Prioritis at Pricing & Market Access Amsterdam
Prioritis will be present at the Pharma Pricing & Market Access Congress Amsterdam, March 19th - 20th 2019 Stand 28 We are proud to...
05
Nov
Prioritis at ISPOR Barcelona – Stand 201
Prioritis is looking forward to seeing you at ISPOR Europe 2018. Barcelona, 12-14 November Stand 201 We are proud to introduce a year...
- 1
- 2